BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp

BioAtla (NASDAQ:BCAB) was downgraded by stock analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.

Separately, Wall Street Zen raised shares of BioAtla from a “sell” rating to a “hold” rating in a research report on Friday, June 6th.

BioAtla Stock Performance

BCAB opened at $0.36 on Wednesday. The stock has a market capitalization of $21.27 million, a P/E ratio of -0.33 and a beta of 0.90. The company’s 50-day simple moving average is $0.39 and its two-hundred day simple moving average is $0.39. BioAtla has a 52-week low of $0.24 and a 52-week high of $2.53.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Research analysts forecast that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAtla

Several hedge funds and other institutional investors have recently made changes to their positions in BCAB. Woodline Partners LP purchased a new stake in BioAtla in the 1st quarter worth approximately $26,000. Two Sigma Investments LP increased its holdings in BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after acquiring an additional 61,725 shares in the last quarter. Jane Street Group LLC increased its holdings in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after acquiring an additional 100,204 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in BioAtla in the 4th quarter worth approximately $383,000. Finally, Boxer Capital Management LLC purchased a new stake in BioAtla in the 4th quarter worth approximately $406,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.